Acorah Software Products - Accounts Production 18.1.170 false true 31 March 2025 1 April 2024 false 1 April 2025 31 March 2026 31 March 2026 13242918 B Deldar D Hanbury S Hess iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 13242918 2025-03-31 13242918 2026-03-31 13242918 2025-04-01 2026-03-31 13242918 frs-core:CurrentFinancialInstruments 2026-03-31 13242918 frs-core:Non-currentFinancialInstruments 2026-03-31 13242918 frs-core:ComputerEquipment 2026-03-31 13242918 frs-core:ComputerEquipment 2025-04-01 2026-03-31 13242918 frs-core:ComputerEquipment 2025-03-31 13242918 frs-core:WithinOneYear 2026-03-31 13242918 frs-core:ShareCapital 2026-03-31 13242918 frs-core:RetainedEarningsAccumulatedLosses 2026-03-31 13242918 frs-bus:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 13242918 frs-bus:FilletedAccounts 2025-04-01 2026-03-31 13242918 frs-bus:SmallEntities 2025-04-01 2026-03-31 13242918 frs-bus:AuditExempt-NoAccountantsReport 2025-04-01 2026-03-31 13242918 frs-bus:SmallCompaniesRegimeForAccounts 2025-04-01 2026-03-31 13242918 frs-bus:Director1 2025-04-01 2026-03-31 13242918 frs-bus:Director2 2025-04-01 2026-03-31 13242918 frs-bus:Director3 2025-04-01 2026-03-31 13242918 frs-countries:EnglandWales 2025-04-01 2026-03-31 13242918 2024-03-31 13242918 2025-03-31 13242918 2024-04-01 2025-03-31 13242918 frs-core:CurrentFinancialInstruments 2025-03-31 13242918 frs-core:Non-currentFinancialInstruments 2025-03-31 13242918 frs-core:WithinOneYear 2025-03-31 13242918 frs-core:ShareCapital 2025-03-31 13242918 frs-core:RetainedEarningsAccumulatedLosses 2025-03-31
Registered number: 13242918
Deep-Medical Ltd
Unaudited Financial Statements
For The Year Ended 31 March 2026
Deep-Medical Ltd
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—5

Page 1
Deep-Medical Ltd
Balance Sheet
As At 31 March 2026
Balance Sheet
Registered number: 13242918

| 2026 | 2025 as restated
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Tangible Assets | 5 |  | 9,986 |  | 10,174
|  |  | 9,986 |  | 10,174
CURRENT ASSETS
Debtors | 6 | 203,486 |  | 1,593,243 |
Cash at bank and in hand |  | 442,783 |  | 255,018 |
|  | 646,269 |  | 1,848,261 |
Creditors: Amounts Falling Due Within One Year | 7 | (296,989 ) |  | (876,990 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | 349,280 |  | 971,271
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 359,266 |  | 981,445
Creditors: Amounts Falling Due After More Than One Year | 8 |  | (172,490 ) |  | (670,810 )
NET ASSETS |  |  | 186,776 |  | 310,635
CAPITAL AND RESERVES
Called up share capital | 9 |  | 2,939,946 |  | 2,489,946
Profit and Loss Account |  |  | (2,753,170 ) |  | (2,179,311 )
SHAREHOLDERS' FUNDS |  |  | 186,776 |  | 310,635

Page 1
Page 2
Deep-Medical Ltd
Balance Sheet (continued)
As At 31 March 2026
For the year ending 31 March 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

S Hess Director
13 May 2026

The notes on pages 3 to 5 form part of these financial statements.
Page 2
Page 3
Deep-Medical Ltd
Notes to the Financial Statements
For The Year Ended 31 March 2026
Notes to the Financial Statements
1. General Information
Deep-Medical Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 13242918 . The registered office is 1 Primrose Street, London, EC2A 2JN.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
The presentation currency of the financial statements is £ sterling.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
Sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.
Rendering of services
Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
2.3. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer Equipment | 3 years straight line

2.4. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
2.5. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
...CONTINUED
Page 3
Page 4
Deep-Medical Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 March 2026
2.5. Taxation - continued
Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.
The company recognises research and development tax relief receivable in respect of qualifying expenditure on an accruals basis where entitlement has been established and receipt is considered probable and reliably measured. Amounts recoverable are recognised within taxation in the statement of profit or loss in the period to which the qualifying expenditure relates.
2.6. Pensions
The company operates a defined pension contribution scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 11 (2025: 7)
11 7
4. Prior Period Adjustment
During the year, the company changed its accounting policy in respect of the recognition of research and development tax credits.
Previously, research and development tax credits were recognised in the financial statements on receipt from HM Revenue & Customs. The company now recognises such credits on an accruals basis when entitlement is established, receipt is considered virtually certain, and the amount can be measured reliably.
The directors consider that the revised policy provides more reliable and relevant information regarding the company’s financial performance and position, in accordance with FRS 102.
Comparative figures have been restated. The effect of the change was to decrease profit after taxation for the prior year by £60,059 and increase debtors and retained earnings at 31 March 2025 by £125,145.
5. Tangible Assets

| Computer Equipment
--- | ---
| £
Cost
As at 1 April 2025 | 17,546
Additions | 6,077
As at 31 March 2026 | 23,623
Depreciation
As at 1 April 2025 | 7,372
Provided during the period | 6,265
As at 31 March 2026 | 13,637
Net Book Value
As at 31 March 2026 | 9,986
As at 1 April 2025 | 10,174

Page 4
Page 5
Deep-Medical Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 March 2026
6. Debtors

| 2026 |  | 2025 as restated
--- | --- | --- | ---
| £ |  | £
Due within one year
Trade debtors | 30,000 |  | 1,447,452
Other debtors | 173,486 |  | 145,791
| 203,486 |  | 1,593,243

7. Creditors: Amounts Falling Due Within One Year

| 2026 |  | 2025 as restated
--- | --- | --- | ---
| £ |  | £
Trade creditors | 6,997 |  | 15,723
Other creditors | 262,834 |  | 559,348
Taxation and social security | 27,158 |  | 301,919
| 296,989 |  | 876,990

8. Creditors: Amounts Falling Due After More Than One Year

| 2026 |  | 2025 as restated
--- | --- | --- | ---
| £ |  | £
Other creditors | 172,490 |  | 670,810

9. Share Capital

| 2026 |  | 2025 as restated
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 2,939,946 |  | 2,489,946

10. Other Commitments
The total of future minimum lease payments under non-cancellable operating leases are as following:

| 2026 |  | 2025 as restated
--- | --- | --- | ---
| £ |  | £
Not later than one year | 37,500 |  | -
| 37,500 |  | -

11. Directors Advances, Credits and Guarantees
Included within Debtors is £169 (2025: £271) owed by the directors to the company. This amount is unsecured, interest free and repayable on demand.
12. Transition to FRS 102
During the year, the company ceased to qualify as a micro-entity and has therefore prepared its financial statements in accordance with FRS 102 Section 1A. The prior year comparatives have been restated accordingly.
Page 5